GoodRx to Offer Boehringer Ingelheim’s Humira Biosimilar
Boehringer Ingelheim’s high- and low-concentration adalimumab-adbm will be available through GoodRx for $550 for two-pack, which represents a 92% discount from the Humira list price.
Boehringer Ingelheim is teaming up with GoodRx to provide its citrate-free biosimilar adalimumab-adbm at a cash price that is 92% discount from the Humira list price and 65% off the average retail price of $1,578.99 for adalimumab-adbm.
Adalimumab-adbm is an FDA-approved interchangeable biosimilar to Humira. The citrate-free, injectable medication is used to treat or reduce the signs and symptoms of certain autoimmune conditions, such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and ulcerative colitis.
Beginning today, Boehringer Ingelheim’s unbranded biosimilar is available at more than 70,000 retail pharmacies for $550 for two-pack, which represents a 92% discount from the Humira list price. Both high-concentration and low-concentration citrate-free formulations in a pre-filled syringe or an autoinjector are available.
At the GoodRx website, it is noted that commercially insured patients may eligible for a $0 copay
The Humira biosimilar market has become competitive with now 10 products on the market, and manufacturing companies are developing different strategies.
In May, Boehringer Ingelheim announced that it will be providing adalimumab-adbm through a private-label agreement with Evernorth Health Services. This makes the second company to be manufacturing a private-label Humira biosimilar to Evernorth. Boehringer Ingelheim will be manufacturing adalimumab-adbm for Quallent Pharmaceuticals, Evernorth’s affiliate private label pharmaceutical distributor.
Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize the branded Cyltezo (adalimumab-adbm) injection and the nonbranded adalimumab-adbm.
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
